Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)

Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, patients must commit to lifelong immunosuppressive therapy. Although these immunosuppressive agents offer significant benefits in preventing organ rejection, they pose several risks. Patients on the medications are more susceptible to infections due to their weakened immune system, and there can be long-term side effects such as increased risk of certain cancers and cardiovascular problems. Despite these challenges, the use of immunosuppressive drugs is a critical component of post-transplant care, balancing the need to prevent organ rejection with the management of potential adverse effects. This report closely examines how key immunosuppressive agents are used in newly diagnosed and recently treated kidney transplant patients.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed kidney transplant patients?
• What are the quarterly trends in prescribing among recently treated and newly diagnosed kidney transplant patients?
• How have immunosuppressive therapies been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of kidney transplant patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
• What percentage of kidney transplant patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses.

Market covered: United States

Key drugs: Astagraf XL, Atgam, CellCept, Envarsus XR, Imuran, Lemtrada, Myfortic, Neoral, Nulojix, Prograf, Rapamune, Rituxan, Sandimmune, Simulect, Thymoglobulin, Zortress